Neuro Vive Pharmaceutical AB

April 10, 2013

Today NeuroVive Pharmaceutical AB starts trading on the main market of NASDAQ OMX Stockholm. 
NeuroVive is a Small Cap company within the Healthcare sector, and it was previously listed on Aktietorget. NeuroVive is the first company to list on NASDAQ OMX Nordic main markets this year. NeuroVive will continue to trade under the same ticker symbol, NVP.

NeuroVive is a leading mitochondrial medicine company that is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. Its products, CicloMulsion® and NeuroSTAT®, are special formulations of the cyclophilin inhibitor cyclosporine for two prioritized indications, the prevention of reperfusion injury following stenting after myocardial infarction and traumatic brain injury respectively. CicloMulsion® is currently in a 1,000 patient Phase III trial assessing its ability to reduce overall mortality and the number of patients developing heart failure in patients with myocardial infarction. NeuroSTAT® is soon entering a Phase II clinical trial in patients with traumatic brain injury. For more information, please visit www.neurovive.com.

Follow the NeuroVive share here »

See the webcast from the listing ceremony »


Watch an interview with NeuroVive CEO Mikael Brönnegård (3:23)


NeuroVive put on a song performance in conjunction with the ceremony. Watch below. (6:16)


Photos from the listing ceremony at NASDAQ OMX in Stockholm:

NASDAQ OMX Marie Parck hands over the listing crystal to NeuroVives CEO Mikael Brönnegård

NeuroVives CEO Mikael Brönnegård tolls the bell.

The NeuroVive Team

NeuroVives CEO Mikael Brönnegård together with NASDAQ OMXs Marie Parck